Showing 5331-5340 of 5771 results for "".
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Imprimis Pharmaceuticals Changes Name to Harrow Healthhttps://modernod.com/news/imprimis-pharmaceuticals-changes-name-to-harrow-health/2476233/Imprimis Pharmaceuticals announced it has formally changed its name to Harrow Health and began trading as “HROW” on the NASDAQ Capital Markets on January 2, 2019. “Our new name reflects our business model of c
- Lightmed Founder and Executive Chairman Gary Lee Reassumes CEO Rolehttps://modernod.com/news/lightmed-founder-and-executive-chairman-gary-lee-reassumes-ceo-role/2476234/Lightmed Corporation announced the reappointment of founder and Executive Chairman Gary Lee as Chief Executive Officer, effective immediately. Shlomo Alkalay has accomplished his CEO assignment and will return to his
- Nicox Enters Into Collaboration With Novaliq on Topical Ophthalmic Formulationshttps://modernod.com/news/nicox-enters-into-collaboration-with-novaliq-on-topical-ophthalmic-formulations/2476241/Nicox announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators. As part of this focus, Nicox has entered into a res
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu
- Beaver-Visitec International to Acquire PhysIOL Grouphttps://modernod.com/news/tpg-capital-backs-bvi-to-acquire-physiol-group-sa/2476246/Beaver-Visitec International (BVI) announced it has signed a definitive agreement to acquire PhysIOL Group, a Belgium-based ophthalmic company specializing in the research, development, and manufacture of IOLs, from TA Associates. Financial terms of the transaction were not disclosed.
- Clearside Biomedical Submits NDA for Xipere for the Treatment of Macular Edema Associated with Uveitishttps://modernod.com/news/clearside-biomedical-submits-nda-for-xipere-for-the-treatment-of-macular-edema-associated-with-uveitis/2476247/Clearside Biomedical announced that it has submitted a new drug application (NDA) to the FDA for Xipere for the treatment of macular edema associated with uveitis. If approved by the FDA, Xipere would be the first therapy for macular edema associated with uveitis. “Based on the dat
- Alcon Acquires Tear Film Innovationshttps://modernod.com/news/alcon-announces-acquisition-of-tear-film-innovations/2476248/Alcon announced that it has acquired Tear Film Innovations, maker of the iLux device to treat meibomian gland dysfunction. Financial terms of the deal were not disclosed. Handheld and portable, the iLux enables eye care professionals to directly target a patient’s blocked meibomian
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- For 2019, ADA and ACC Align Their Diabetes Recommendationshttps://modernod.com/news/for-2019-ada-and-acc-align-their-diabetes-recommendations/2476250/For the first time in its annual diabetes management guidelines, the American Diabetes Association (ADA) has aligned its recommendations with those of the American College of Cardiology (ACC) for cardiovascular risk reduction in people with type 2 diabetes, according to a report in Medscape.